Cambridge, Massachusetts-based Cognito designed its non-invasive neuromodulation device to deliver proprietary gamma frequency light and sound stimulation. This evokes EEG-confirmed gamma frequency brain oscillations to treat central nervous system (CNS) diseases.
The therapy may reduce functional and cognitive decline and brain atrophy in individuals with mild-to-moderate Alzheimer’s. That includes specific reductions in white matter volume loss and myelin preservation.
Spectris provides a potentially disease-modifying, non-pharmacologic alternative to current AD treatments. The cost-effectiveness model highlights the potential for Spectris to reduce patient costs and alleviate the financial burden of healthcare systems. Cognito presented the data at the International Society for Pharmacoeconomics and Outcomes Research Europe (ISPOR Europe) 2024 annual meeting in Barcelona.
The model demonstrated the early cost-effectiveness of Spectris as an alternative to currently available treatment options. Investigators analyzed data from the Phase II OVERTURE study to estimate Spectris’ economic value for mild-to-moderate AD patients. Cognito said findings included cost-effectiveness at an acquisition cost ranging from $44,000 to $108,000, based on various efficacy scenarios and a $100,000 willingness-to-pay (WTP) threshold. The model also projects an additional life year (LY) and 1.13 quality-adjusted life years (QALYs) gained with Spectris.
Cognito said the data underlined the treatment’s potential to enhance patient outcomes over a patient’s lifetime.
“Spectris is anticipated to reduce annual care expenses by providing a durable, cost-effective option without the significant side effects and ongoing treatment costs associated with the newly approved monoclonal antibodies,” said Dr. Ralph Kern, chief medical officer. “Spectris aims to fill a critical unmet need in AD care, by potentially providing a safe treatment that improves patient outcomes while limiting the financial burden on patients and the healthcare system.”
